The results show that ant-134 treatment is not effective in suppressing seizures in F1.Scn1a(+/−)tm1kea mice, suggesting that miR-134 is not able to modulate the epileptogenic process in DS and does not represent a therapeutic target for the disease. The gene discussed is SCN1A; the disease is Dravet syndrome.